Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Livingston › NPI 1396857488
Hospital

Cooperman Barnabas Medical Center INC

Cooperman Barnabas Medical Center INC was paid $136.81M by Medicaid between Jan 2018 and Dec 2024, across 483 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.

33Billing provider infoCOOPERMAN BARNABAS MEDICAL CENTER INC
LIVINGSTON, NJ 07039
33aNPI1396857488assigned 08/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$136.81M
24GClaims1,999,431
24DCodes billed483
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in New Jersey

Rank by total paid#13 of 93
Median peer was paid$30.60M
This provider vs. median4.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official DAVIS, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M$3.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018239,208$19.72M
2019248,376$18.59M
2020191,975$13.25M
2021249,620$18.62M
2022353,918$20.38M
2023402,914$24.83M
2024incomplete313,420$21.41M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 19% 68,486 64,802 $25.40M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 15% 45,204 42,454 $20.49M
G0378 Hospital observation service, per hour 13% 21,709 19,156 $18.41M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 11% 34,725 31,189 $14.66M
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete 3.0% 5,747 5,421 $4.14M
OP250 3.0% 121,944 89,555 $4.04M
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.4% 14,929 14,237 $3.32M
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance 2.2% 9,321 5,574 $3.03M
J2350 Injection, ocrelizumab, 1 mg 1.6% 130 99 $2.19M
80053 Comprehensive metabolic panel 1.6% 115,674 87,478 $2.18M
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 1.3% 776 755 $1.71M
96375 Therapeutic injection; each additional sequential IV push <1% 24,631 18,775 $1.23M
471 more codes
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 34,036 $1.13M
93017 <1% 2,969 $1.13M
71046 Radiologic examination, chest; 2 views <1% 21,932 $1.12M
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 7,552 $993K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 3,698 $977K
95810 Polysomnography; sleep staging with 4 or more additional parameters <1% 295 $885K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 25,383 $787K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 2,288 $768K
OP370 <1% 9,914 $767K
96415 <1% 2,381 $734K
96361 Intravenous infusion, hydration; each additional hour <1% 24,242 $732K
Q5117 Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg <1% 256 $716K
J2323 Injection, natalizumab, 1 mg <1% 187 $686K
36415 Collection of venous blood by venipuncture <1% 140,300 $685K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 34,773 $590K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 7,359 $588K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 110,072 $579K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 14,254 $575K
93970 <1% 2,213 $539K
OP272 <1% 13,353 $531K
71045 Radiologic examination, chest; single view <1% 11,401 $525K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 26,554 $521K
OP710 <1% 10,305 $502K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 4,434 $493K
C1713 Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) <1% 639 $480K
C1776 Joint device (implantable) <1% 236 $433K
93458 <1% 337 $427K
96417 <1% 2,069 $417K
30140 <1% 229 $409K
70450 Computed tomography, head or brain; without contrast material <1% 7,848 $374K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 29,390 $362K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 4,387 $359K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 9,207 $329K
93971 <1% 1,973 $320K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 7,878 $314K
OP258 <1% 45,262 $310K
96367 <1% 2,475 $307K
81001 <1% 53,913 $245K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 12,356 $243K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 3,221 $240K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 8,191 $235K
86850 <1% 14,757 $233K
J9271 Injection, pembrolizumab, 1 mg <1% 38 $225K
92587 <1% 1,199 $221K
99213 Doctor's office visit, returning patient (routine) <1% 4,892 $220K
97802 <1% 1,105 $202K
76770 <1% 1,703 $199K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 2,386 $198K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 2,279 $195K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 18,005 $181K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 5,529 $174K
77336 <1% 1,150 $172K
J2469 Injection, palonosetron hcl, 25 mcg <1% 1,674 $163K
80197 <1% 17,209 $163K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 4,268 $162K
OP270 <1% 4,650 $160K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 2,655 $158K
77334 <1% 279 $154K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 2,509 $154K
85027 <1% 19,356 $149K
J2505 Injection, pegfilgrastim, 6 mg <1% 34 $149K
97014 <1% 3,568 $147K
80048 Basic metabolic panel (calcium, ionized) <1% 10,965 $146K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 4,214 $142K
92567 <1% 1,864 $140K
73564 <1% 3,326 $140K
71275 Computed tomographic angiography, chest, with contrast material <1% 1,399 $137K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 202 $132K
73630 <1% 3,180 $132K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 4,325 $130K
87081 <1% 4,642 $128K
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose <1% 2,265 $124K
J0897 Injection, denosumab, 1 mg <1% 79 $124K
74021 <1% 3,161 $122K
73030 <1% 2,111 $119K
G0379 Direct admission of patient for hospital observation care <1% 2,424 $118K
83735 <1% 27,104 $117K
86900 <1% 16,541 $117K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 2,867 $113K
80061 Lipid panel <1% 8,067 $107K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 1,322 $107K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 5,239 $106K
96411 <1% 325 $104K
95816 <1% 402 $102K
97161 <1% 3,080 $101K
87086 Culture, bacterial; quantitative colony count, urine <1% 17,848 $101K
97803 <1% 625 $97K
82962 <1% 11,467 $96K
82043 <1% 3,126 $96K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 4,939 $95K
85610 <1% 18,103 $94K
87799 <1% 6,209 $92K
76830 Ultrasound, transvaginal <1% 1,623 $92K
73130 <1% 2,144 $89K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,458 $88K
94729 <1% 673 $87K
J1756 Injection, iron sucrose, 1 mg <1% 2,378 $86K
70551 Magnetic resonance imaging, brain; without contrast material <1% 460 $84K
84443 Thyroid stimulating hormone (TSH) <1% 8,134 $81K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 3,006 $79K
73610 <1% 2,788 $78K
97535 Self-care/home management training, each 15 minutes <1% 3,124 $78K
83970 <1% 2,766 $76K
72125 Computed tomography, cervical spine; without contrast material <1% 1,528 $75K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 412 $74K
74018 <1% 1,947 $74K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 3,169 $74K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 5,544 $72K
87631 <1% 3,122 $72K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 11,411 $69K
94060 <1% 314 $69K
82378 <1% 3,203 $68K
72100 <1% 1,909 $66K
84100 <1% 22,273 $66K
96401 <1% 460 $65K
86803 <1% 14,288 $64K
92557 <1% 437 $64K
82803 <1% 3,057 $63K
86901 <1% 16,628 $62K
OP278 <1% 129 $62K
36430 <1% 600 $62K
85730 <1% 12,849 $59K
16020 <1% 1,050 $58K
73110 <1% 1,349 $57K
87070 <1% 4,032 $57K
99214 Doctor's office visit, returning patient (more involved) <1% 602 $57K
J1439 Injection, ferric carboxymaltose, 1 mg <1% 91 $57K
A9270 Non-covered item or service <1% 14,898 $53K
83036 Hemoglobin; glycosylated (A1C) <1% 9,408 $52K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 3,293 $52K
82542 <1% 1,958 $52K
87040 <1% 4,437 $52K
J2785 Injection, regadenoson, 0.1 mg <1% 1,056 $52K
86300 <1% 1,605 $51K
97162 <1% 1,798 $51K
84550 <1% 15,144 $51K
80047 <1% 5,069 $47K
82728 <1% 3,946 $46K
84156 <1% 8,701 $43K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,138 $42K
96402 <1% 560 $42K
76801 <1% 474 $41K
83615 <1% 13,781 $41K
92552 <1% 439 $41K
84702 <1% 5,782 $39K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 5,423 $39K
81003 <1% 12,620 $39K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 3,901 $39K
81025 <1% 6,680 $36K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 491 $34K
73590 <1% 785 $34K
74022 <1% 466 $34K
83880 <1% 4,342 $33K
84484 <1% 11,023 $32K
30520 <1% 28 $32K
99215 Doctor's office visit, returning patient (complex) <1% 227 $32K
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg <1% 28 $31K
77290 <1% 56 $30K
88342 <1% 1,870 $29K
96416 <1% 110 $29K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 8,199 $29K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 2,284 $27K
87186 <1% 3,171 $27K
76775 <1% 240 $26K
C9290 Injection, bupivacaine liposome, 1 mg <1% 503 $24K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 6,901 $24K
73502 <1% 1,237 $24K
96376 <1% 2,848 $24K
J2704 Injection, propofol, 10 mg <1% 6,930 $24K
C1769 Guide wire <1% 1,906 $23K
84439 <1% 2,485 $23K
83550 <1% 3,316 $23K
J3535 Drug administered through a metered dose inhaler <1% 539 $22K
87340 <1% 7,322 $22K
83690 <1% 17,819 $22K
82570 <1% 6,628 $20K
83540 <1% 3,774 $20K
73140 <1% 571 $20K
77300 <1% 87 $20K
94760 <1% 388 $19K
72040 <1% 449 $18K
82607 <1% 2,383 $18K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 368 $18K
10060 <1% 431 $17K
85007 <1% 5,833 $17K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 2,561 $17K
87088 <1% 5,224 $17K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 4,585 $16K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 923 $16K
87497 <1% 822 $16K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 348 $16K
83605 <1% 3,558 $16K
G0382 Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) <1% 369 $16K
12011 <1% 352 $15K
G0008 Administration of influenza virus vaccine <1% 1,407 $15K
71250 <1% 125 $15K
G0257 Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility <1% 36 $15K
92579 <1% 66 $14K
J1644 Injection, heparin sodium, per 1000 units <1% 2,371 $14K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 13,386 $14K
97165 <1% 515 $14K
P9016 Red blood cells, leukocytes reduced, each unit <1% 347 $13K
50200 <1% 14 $13K
86140 <1% 6,462 $13K
92555 <1% 113 $13K
97116 <1% 985 $13K
70486 <1% 225 $12K
J1170 Injection, hydromorphone, up to 4 mg <1% 4,757 $12K
88304 <1% 1,361 $12K
87077 <1% 2,011 $12K
29125 <1% 405 $12K
85055 <1% 853 $12K
82784 <1% 241 $11K
82746 <1% 1,619 $11K
94727 <1% 162 $11K
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 1,075 $11K
73562 <1% 266 $10K
87807 <1% 1,332 $10K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 972 $10K
29581 <1% 336 $10K
93880 <1% 27 $10K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 17,002 $10K
73080 <1% 502 $10K
83655 <1% 300 $10K
74019 <1% 219 $9K
J1453 Injection, fosaprepitant, 1 mg <1% 230 $9K
85014 <1% 7,289 $9K
85651 <1% 3,699 $9K
12001 <1% 265 $9K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 67 $9K
J0690 Injection, cefazolin sodium, 500 mg <1% 2,384 $9K
86920 <1% 295 $8K
87147 <1% 831 $8K
88307 <1% 234 $8K
87522 Neg quan hep c or qual rna <1% 794 $8K
95800 <1% 12 $8K
85378 <1% 3,415 $8K
76870 <1% 115 $8K
84480 <1% 826 $8K
84145 <1% 1,007 $8K
87999 <1% 38 $8K
87430 <1% 239 $7K
93923 <1% 14 $7K
87486 <1% 966 $7K
C1894 Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser <1% 1,191 $7K
96368 <1% 195 $7K
87641 <1% 738 $7K
90677 <1% 449 $7K
86706 <1% 952 $7K
90715 <1% 1,630 $6K
85045 <1% 2,250 $6K
97597 <1% 54 $6K
87205 <1% 2,694 $6K
90686 <1% 1,216 $6K
86592 <1% 1,686 $6K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 79 $6K
73090 <1% 185 $6K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 115 $5K
A9575 Injection, gadoterate meglumine, 0.1 ml <1% 286 $5K
J2270 Injection, morphine sulfate, up to 10 mg <1% 2,094 $5K
90472 Immunization administration, each additional vaccine (list separately) <1% 789 $5K
90791 Psychiatric diagnostic evaluation <1% 270 $5K
87581 <1% 968 $5K
84134 <1% 967 $5K
82248 <1% 615 $5K
82553 <1% 2,196 $5K
92523 <1% 56 $5K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 4,429 $4K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 3,652 $4K
0001A <1% 127 $4K
80074 <1% 254 $4K
82550 <1% 2,628 $4K
J9217 Leuprolide acetate (for depot suspension), 7.5 mg <1% 31 $4K
77280 <1% 32 $4K
82652 <1% 129 $4K
97150 Therapeutic procedure(s), group (2 or more individuals) <1% 1,495 $4K
82950 <1% 211 $4K
87536 <1% 206 $4K
82150 <1% 2,030 $4K
M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring <1% 99 $4K
93975 <1% 14 $3K
G0009 Administration of pneumococcal vaccine <1% 528 $3K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 2,965 $3K
0002A <1% 111 $3K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 12 $3K
84436 <1% 666 $3K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 261 $3K
82947 <1% 1,645 $3K
80164 <1% 693 $3K
87075 <1% 323 $3K
83521 <1% 106 $3K
C1887 Catheter, guiding (may include infusion/perfusion capability) <1% 504 $3K
J1815 Injection, insulin, per 5 units <1% 1,029 $3K
M0222 Intravenous injection, bebtelovimab, includes injection and post administration monitoring <1% 32 $3K
97022 <1% 220 $3K
86334 <1% 172 $3K
95951 <1% 35 $3K
86336 <1% 108 $3K
82985 <1% 443 $3K
J2060 Injection, lorazepam, 2 mg <1% 722 $3K
88300 <1% 75 $3K
M0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring <1% 89 $3K
Q0247 Injection, sotrovimab, 500 mg <1% 24 $3K
85652 <1% 1,149 $2K
15853 <1% 97 $2K
88311 <1% 301 $2K
84165 <1% 396 $2K
36416 <1% 810 $2K
83883 <1% 210 $2K
90670 <1% 32 $2K
73552 <1% 57 $2K
M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring <1% 55 $2K
90381 <1% 17 $2K
85379 <1% 675 $2K
J9190 Injection, fluorouracil, 500 mg <1% 168 $2K
36591 <1% 159 $2K
82330 <1% 418 $2K
83021 <1% 101 $2K
J0640 Injection, leucovorin calcium, per 50 mg <1% 116 $2K
76776 <1% 32 $2K
80320 <1% 934 $2K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 175 $2K
84153 <1% 107 $2K
80348 <1% 57 $1K
99205 Prolong outpt/office vis <1% 12 $1K
M0247 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring <1% 37 $1K
80179 <1% 407 $1K
80177 <1% 369 $1K
86038 <1% 233 $1K
87517 <1% 147 $1K
OP637 <1% 1,431 $1K
C1760 Closure device, vascular (implantable/insertable) <1% 30 $1K
A9585 Injection, gadobutrol, 0.1 ml <1% 82 $1K
86160 <1% 45 $1K
84703 <1% 187 $1K
82247 <1% 79 $1K
80358 <1% 57 $1K
88313 <1% 50 $1K
92522 <1% 13 $1K
Q3014 Telehealth originating site facility fee <1% 238 $1K
29505 <1% 36 $974.33
J0171 Injection, adrenalin, epinephrine, 0.1 mg <1% 292 $910.71
29515 <1% 39 $894.24
C2617 Stent, non-coronary, temporary, without delivery system <1% 14 $830.46
84132 <1% 1,280 $825.71
84520 <1% 1,607 $814.23
J9263 Injection, oxaliplatin, 0.5 mg <1% 21 $785.44
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 217 $778.74
99203 Doctor's office visit, new patient (routine) <1% 29 $767.18
80051 <1% 368 $751.93
95700 <1% 27 $735.94
86762 <1% 126 $721.68
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 687 $681.82
96523 <1% 15 $681.52
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 1,297 $676.89
OP229 <1% 13 $667.29
82465 <1% 163 $658.30
L4350 Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf <1% 72 $600.56
81401 <1% 26 $598.00
84295 <1% 1,171 $592.15
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 45 $585.79
90651 <1% 57 $584.28
80143 <1% 136 $572.60
J2543 Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) <1% 194 $547.38
82565 <1% 380 $519.90
85008 <1% 1,750 $512.47
82610 <1% 32 $504.35
99201 <1% 13 $488.06
84481 <1% 120 $485.71
0031A <1% 32 $479.67
86704 <1% 71 $465.61
86304 <1% 97 $465.59
85018 <1% 214 $465.52
86308 <1% 530 $452.62
88142 <1% 12 $431.10
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 72 $422.21
72170 <1% 45 $417.90
87493 <1% 92 $404.67
97164 <1% 12 $364.52
86769 <1% 12 $349.86
86617 <1% 24 $341.43
86790 <1% 27 $322.18
12002 <1% 16 $320.50
29130 <1% 34 $313.32
J3370 Injection, vancomycin hcl, 500 mg <1% 426 $303.35
89230 <1% 12 $294.79
82435 <1% 1,029 $270.48
86301 <1% 32 $263.95
73560 <1% 12 $258.13
80329 <1% 66 $256.68
82951 <1% 95 $252.56
82670 <1% 14 $237.25
J3480 Injection, potassium chloride, per 2 meq <1% 117 $235.44
80076 <1% 103 $217.15
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 60 $211.37
82232 <1% 15 $204.24
74420 <1% 17 $178.62
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 448 $169.99
77012 <1% 30 $156.76
87045 <1% 27 $154.04
M0244 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency <1% 20 $130.00
88112 <1% 72 $122.46
L1830 Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf <1% 18 $120.30
88341 <1% 13 $116.02
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 615 $115.77
J0689 Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg <1% 88 $113.91
87046 <1% 14 $113.42
J9045 Injection, carboplatin, 50 mg <1% 28 $110.04
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg <1% 15 $108.90
J1940 Injection, furosemide, up to 20 mg <1% 167 $107.47
85041 <1% 129 $103.20
90656 <1% 61 $102.94
90716 <1% 183 $84.62
80158 <1% 25 $80.20
87640 <1% 534 $72.76
J1596 Injection, glycopyrrolate, 0.1 mg <1% 279 $71.96
J1171 Injection, hydromorphone, 0.1 mg <1% 122 $69.80
OP255 <1% 543 $68.63
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg <1% 74 $64.34
87899 <1% 15 $61.07
88348 <1% 12 $59.71
90681 <1% 195 $58.66
88329 <1% 25 $57.86
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 170 $57.17
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg <1% 52 $54.86
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 881 $54.80
J3475 Injection, magnesium sulfate, per 500 mg <1% 129 $53.31
85347 <1% 19 $49.44
87427 <1% 14 $45.80
J1030 Injection, methylprednisolone acetate, 40 mg <1% 68 $44.86
75571 <1% 13 $43.42
87206 <1% 12 $39.56
J2370 Injection, phenylephrine hcl, up to 1 ml <1% 80 $34.05
90648 <1% 408 $31.70
J0360 Injection, hydralazine hcl, up to 20 mg <1% 129 $29.33
J2371 Injection, phenylephrine hydrochloride, 20 micrograms <1% 346 $29.12
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg <1% 23 $26.00
J7510 Prednisolone oral, per 5 mg <1% 146 $25.73
87102 <1% 32 $24.00
82010 <1% 33 $22.29
J3371 Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg <1% 175 $21.63
J0687 Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg <1% 317 $21.28
J1010 Injection, methylprednisolone acetate, 1 mg <1% 38 $20.39
Q0245 Injection, bamlanivimab and etesevimab, 2100 mg <1% 90 $19.00
J1650 Injection, enoxaparin sodium, 10 mg <1% 19 $15.30
P9603 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled <1% 6,864 $14.14
J1580 Injection, garamycin, gentamicin, up to 80 mg <1% 31 $13.36
J1020 Injection, methylprednisolone acetate, 20 mg <1% 17 $12.18
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 273 $12.00
Q0239 Injection, bamlanivimab-xxxx, 700 mg <1% 57 $12.00
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 268 $12.00
90633 <1% 231 $10.98
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 16 $8.66
J2004 Injection, lidocaine hcl with epinephrine, 1 mg <1% 32 $7.66
C1758 Catheter, ureteral <1% 84 $7.15
Q0222 Injection, bebtelovimab, 175 mg <1% 32 $6.00
J2470 Injection, pantoprazole sodium, 40 mg <1% 19 $4.78
Q0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg <1% 52 $4.00
Q0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg <1% 16 $2.00
Q0244 Injection, casirivimab and imdevimab, 1200 mg <1% 38 $2.00
J0461 Injection, atropine sulfate, 0.01 mg <1% 27 $1.63
90723 0% 316 $0.00
90696 0% 30 $0.00
J2795 Injection, ropivacaine hydrochloride, 1 mg 0% 13 $0.00
87116 0% 15 $0.00
90697 0% 21 $0.00
90707 0% 184 $0.00
90734 0% 13 $0.00
91300 0% 238 $0.00
86618 0% 13 $0.00
90700 0% 47 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDAVIS, RICHARD (PRESIDENT/CEO)
Parent organizationRWJ BARNABAS HEALTH INC
Same official

Other billing entities under DAVIS, RICHARD

Full network →
ProviderLocationPaid
Lucy Webb Hayes National Training School for Deaconesses & MissionarieWashington, DC$19.10M
Linq Care INCNaperville, IL$6.72M
Innovative Family Services, LLCMechanicsville, VA$6.26M
Central Peninsula General Hospital, INCSoldotna, AK$5.93M
Central Peninsula General Hospital, INCKenai, AK$5.03M
Central Peninsula General Hospital, INCSoldotna, AK$2.61M
Central Peninsula General Hospital INCSoldotna, AK$1.23M
Central Peninsula General Hospital, INCSoldotna, AK$938K
Central Peninsula General Hospital, INCKenai, AK$604K
Central Peninsula General Hospital INCKenai, AK$432K
Central Peninsula General Hospital INCSoldotna, AK$230K
Central Peninsula General Hospital, INCSoldotna, AK$156K
Central Peninsula General Hospital, INCSoldotna, AK$106K
Central Peninsula General Hospital, INCSoldotna, AK$101K
Central Peninsula General Hospital INCSoldotna, AK$95K
Stephanie Cropper, MD, INC.Pomona, CA$93K
Central Peninsula General Hospital INCSoldotna, AK$62K
Central Peninsula General Hospital, INCSoldotna, AK$51K
R Keith Davis MD PLLC PASmackover, AR$24K
Linq Care Medical Provider, LLC.Marlton, NJ$60.93

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.